Find clinical trials

This research study is looking at whether the oral supplement TRU NIAGEN®, a form of Vitamin B, can increase the levels of the molecule NAD+ in the blood and heart muscle. NAD+ is essential for energy production in the human body. Research has shown decreased NAD+ levels in the heart muscle of patients with a condition of heart failure known as heart failure with preserved ejection fraction (HFpEF) or stiff heart failure. TRU NIAGEN® has been shown to increase the level of NAD+ in the blood, however whether it can increase NAD+ in the heart muscle is unknown. Replenishing NAD+ in the heart could be beneficial to HFpEF patients and/ or patients whose hearts don’t relax properly. The aim of the study is to see whether taking the oral supplement TRU NIAGEN® for three months can improve your heart function, exercise tolerance, glucose tolerance, and blood pressure.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia globally contributing significantly to cardiovascular morbidity and mortality. Obesity is a well-established modifiable risk factor for AF and is present in 2/3 of patients with AF. The SEMOAF study aims to randomise 220 patients with AF and overweight/obesity to semaglutide 2.4 mg weekly vs placebo to determine the impact of weight loss on AF recurrence and burden.

We are inviting patients who undergo thyroid nodular ablation to allow us to include their coded treatment and outcome information in the study so we can better understand the effectiveness and safety of the procedure over time. Thyroid nodular ablation is a relatively new treatment in Australia, first introduced in April 2021, and there is still limited information about its long-term outcomes. To help strengthen this knowledge, we are conducting the thyroid ablation study (the TArgeT study).

Significant blood dilution occurs during cardiac surgery involving cardiopulmonary bypass. One way to minimise this is a technique called retrograde autologous priming (RAP) whereby the patient’s own blood is used to prime the bypass circuit instead of a clear fluid solution. This study aims to assess the feasibility of a full-scale trial to determine if the routine use of RAP decreases the amount of blood transfused up to 72 hours post-surgery.

Many people with epilepsy still have seizures despite medication, and current treatments like surgery or deep brain stimulation don't work for everyone. This study will use temporary electrodes placed in deeper parts of the brain during routine epilepsy evaluations to test different stimulation approaches, helping doctors find the best personalised treatment for each person.

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.

This trial aims to investigate the safety and efficacy of Multiple Subcutaneous Doses of TRB-061 in patients with moderate-to-severe Atopic Dermatitis. Participants will receive doses of study treatment for up to 6 months (24 months). This would include administering doses of study treatment (TRB-061 24mg or 50mg subcutaneous injections) or placebo every 4 weeks over 12 weeks in period 1. In period 2, another 4 doses of treatment with increased dose of 50mg, will be given over 12 weeks to all participants, including those who received placebo in period 1. Participants are expected to visit study clinic 16 times during trial.

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology.